nach oben

Erschienen in:

01.03.2014 | Original Article

Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial

verfasst von: Wen-Hao Tang, Fu-Huang Lin, Chien-Hsing Lee, Feng-Chih Kuo, Chang-Hsun Hsieh, Fone-Ching Hsiao, Yi-Jen Hung

Erschienen in: Endocrine | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Cilostazol is an antiplatelet, antithrombotic agent with anti-inflammatory properties. To date, no clinical study has specifically evaluated the efficacy of cilostazol in patients with diabetic nephropathy (DN). We hypothesized that cilostazol might delay renal deterioration in DN patients at high risk of progression. Between April 2008 and April 2010, we screened 156 consecutive patients aged 35–80 years who were first diagnosed with type 2 diabetes after the age of 30 years. Of these, 90 patients with DN, as defined by morning spot urine microalbuminuria (MAU) >20 mg/L or an albumin-to-creatinine ratio (ACR) >30 μg/mg on at least two consecutive occasions within the prior 3 months, were enrolled into a 52-week randomized, single-blinded, placebo-controlled trial of oral cilostazol 100 mg twice daily or placebo (45 subjects in each group). Morning spot urine samples were collected to determine MAU and ACR. Fasting plasma levels of metabolic, endothelial variables, and inflammatory markers were examined. Following 52 weeks of treatment, urinary MAU and ACR were significantly reduced in the cilostazol group compared with the placebo group (P = 0.024 and P = 0.02, respectively). In regression analyses, changes in monocyte chemotactic protein-1, E-selectin, and soluble vascular cell adhesion molecule-1 (sVCAM-1) were significantly associated with changes in MAU and ACR. Net changes of E-selectin (P < 0.001) and sVCAM-1 (P < 0.05) were independent predictors of change in MAU and ACR, respectively. Our results suggest that cilostazol may effectively attenuate deterioration of albuminuria in patients with type 2 diabetes. This effect is likely mediated by an improvement of adhesion molecules.

C.E. Lok, M.J. Oliver, D.M. Rothwell, J.E. Hux, The growing volume of diabetes-related dialysis: a population based study. Nephrol. Dial. Transplant. 19, 3098–3103 (2004)PubMedCrossRef

G. Jerums, S. Panagiotopoulos, E. Premaratne, R.J. MacIsaac, Integrating albuminuria and GFR in the assessment of diabetic nephropathy. Nat. Rev. Nephrol. 5, 397–406 (2009)PubMedCrossRef

G. Remuzzi, A. Schieppati, P. Ruggenenti, Clinical practice. Nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 346, 1145–1151 (2002)PubMedCrossRef

A.I. Adler, R.J. Stevens, S.E. Manley, R.W. Bilous, C.A. Cull, R.R. Holman, UKPDS Group, Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 63, 225–232 (2003)PubMedCrossRef

M.A. Gall, Albuminuria in non-insulin-dependent diabetes mellitus. Prevalence, causes, and consequences. Dan. Med. Bull. 44, 465–485 (1997)PubMed

R. Retnakaran, C.A. Cull, K.I. Thorne, A.I. Adler, R.R. Holman, UKPDS Study Group, Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 55, 1832–1839 (2006)PubMedCrossRef

C. Forsblom, V. Harjutsalo, L.M. Thorn et al., Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. J. Am. Soc. Nephrol. 22, 537–544 (2001)CrossRef

A. Patel, S. MacMahon, J. Chalmers et al., Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560–2572 (2008)PubMedCrossRef

K. Phisitkul, K. Hegazy, T. Chuahirun et al., Continued smoking exacerbates but cessation ameliorates progression of early type 2 diabetic nephropathy. Am. J. Med. Sci. 335, 284–291 (2008)PubMedCrossRef

10.

G. Deferrari, M. Ravera, V. Berruti, G. Leoncini, L. Deferrari, Optimizing therapy in the diabetic patient with renal disease: antihypertensive treatment. J. Am. Soc. Nephrol. 15(Suppl 1), S6–S11 (2004)PubMedCrossRef

11.

G.F. Strippoli, C. Bonifati, M. Craig, S.D. Navaneethan, J.C. Craig, Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst. Rev. CD006257 (2006)

12.

B.B. McCormick, A. Sydor, A. Akbari, D. Fergusson, S. Doucette, G. Knoll, The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. Am. J. Kidney Dis. 52, 454–463 (2008)PubMedCrossRef

13.

J.F. Navarro, C. Mora, M. Muros et al., Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J. Am. Soc. Nephrol. 16, 2119–2126 (2005)PubMedCrossRef

14.

J.F. Navarro, C. Mora, M. Muros, J. García, Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am. J. Kidney Dis. 33, 458–463 (1999)PubMedCrossRef

15.

Y.M. Chen, S.L. Lin, W.C. Chiang, K.D. Wu, T.J. Tsai, Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases. Kidney Int. 69, 1410–1415 (2006)PubMed

16.

A. Giustina, S. Bossoni, A. Cimino et al., Picotamide, a dual TXB synthase inhibitor and TXB receptor antagonist reduces exercise-induced albuminuria in microalbuminuric patients with NIDDM. Diabetes 42, 178–182 (1993)PubMedCrossRef

17.

A. Giustina, P. Perini, P. Desenzani et al., Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients. Diabetes 47, 423–430 (1998)PubMedCrossRef

18.

T. Shinoda-Tagawa, Y. Yamasaki, S. Yoshida et al., A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with type II diabetes. Diabetologia 45, 188–194 (2002)PubMedCrossRef

19.

P.D. Thompson, R. Zimet, W.P. Forbes, P. Zhang, Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am. J. Cardiol. 90, 1314–1319 (2002)PubMedCrossRef

20.

N.K. Agrawal, R. Maiti, D. Dash, B.L. Pandey, Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients. Pharmacol. Res. 56, 118–123 (2007)PubMedCrossRef

21.

M.J. Kim, K.G. Park, K.M. Lee et al., Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F. Hypertension 45, 552–556 (2005)PubMedCrossRef

22.

S.M. Grenon, J. Gagnon, Y. Hsiang et al., Video in clinical medicine. Ankle-brachial index for assessment of peripheral arterial disease. N. Engl. J. Med. 361(19), e40 (2009)PubMedCrossRef

23.

L. Gao, F. Wang, B. Wang et al., Cilostazol protects diabetic rats from vascular inflammation via nuclear factor-kappa B-dependent down-regulation of vascular cell adhesion molecule-1 expression. J. Pharmacol. Exp. Ther. 318, 53–58 (2006)PubMedCrossRef

24.

Y. Hattori, K. Suzuki, A. Tomizawa et al., Cilostazol inhibits cytokine-induced nuclear factor-kappa B activation via AMP-activated protein kinase activation in vascular endothelial cells. Cardiovasc. Res. 81, 133–139 (2009)PubMedCrossRef

25.

F. Wang, M. Li, L. Cheng et al., Intervention with cilostazol attenuates renal inflammation in streptozotocin-induced diabetic rats. Life Sci. 83, 828–835 (2008)PubMedCrossRef

26.

X. Wang, L. Yan, W. Chen, L. Xu, X. Zhang, The renal protective effects of cilostazol on suppressing pathogenic thrombospondin-1 and transforming growth factor-beta expression in streptozotocin-induced diabetic rats. J. Int. Med. Res. 37, 145–153 (2009)PubMedCrossRef

27.

J. Watanabe, Y. Sako, F. Umeda, H. Nawata, Effects of cilostazol, a phosphodiesterase inhibitor, on urinary excretion of albumin and prostaglandins in non-insulin-dependent diabetic patients. Diabetes Res. Clin. Pract. 22, 53–59 (1993)PubMedCrossRef

28.

S.L. Lin, Y.M. Chen, C.T. Chien, W.C. Chiang, C.C. Tsai, T.J. Tsai, Pentoxifylline attenuated the renal disease progression in rats with remnant kidney. J. Am. Soc. Nephrol. 13, 2916–2929 (2002)PubMedCrossRef

29.

A. Yagmurlu, M.E. Boleken, D. Ertoy, M. Ozsan, I.H. Gokcora, H. Dindar, Preventive effect of pentoxifylline on renal scarring in rat model of pyelonephritis. Urology 61, 1037–1041 (2003)PubMedCrossRef

30.

N. Katakami, Y.S. Kim, R. Kawamori, Y. Yamasaki, The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial. Circulation 121, 2584–2591 (2010)PubMedCrossRef

31.

R.B. Goldberg, Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J. Clin. Endocrinol. Metab. 94, 3171–3182 (2009)PubMedCrossRef

32.

P. Clausen, P. Jacobsen, K. Rossing, J.S. Jensen, H.H. Parving, B. Feldt-Rasmussen, Plasma concentrations of VCAM-1 and ICAM-1 are elevated in patients with type 1 diabetes mellitus with microalbuminuria and overt nephropathy. Diabet. Med. 17, 644–649 (2000)PubMedCrossRef

33.

J. Lin, F.B. Hu, E.B. Rimm, N. Rifai, G.C. Curhan, The association of serum lipids and inflammatory biomarkers with renal function in men with type II diabetes mellitus. Kidney Int. 69, 336–342 (2006)PubMedCentralPubMedCrossRef

34.

E. Galkina, K. Ley, Vascular adhesion molecules in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 27, 2292–2301 (2007)PubMedCrossRef

35.

F. Chiarelli, F. Cipollone, A. Mohn et al., Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes. Diabetes Care 25, 1829–1834 (2002)PubMedCrossRef

36.

K. Tashiro, I. Koyanagi, A. Saitoh et al., Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy. J. Clin. Lab. Anal. 16(1), 1–4 (2002)PubMedCrossRef

37.

T. Morii, H. Fujita, T. Narita et al., Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy. J. Diabetes Complications 17, 11–15 (2003)PubMedCrossRef

38.

F.Y. Chow, D.J. Nikolic-Paterson, E. Ozols, R.C. Atkins, B.J. Rollin, G.H. Tesch, Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int. 69, 73–80 (2006)PubMedCrossRef

39.

K. Ina, H. Kitamura, T. Okeda et al., Vascular cell adhesion molecule-1 expression in the renal interstitium of diabetic KKAy mice. Diabetes Res. Clin. Pract. 44, 1–8 (1999)PubMedCrossRef

40.

S.C. Lim, A.E. Caballero, P. Smakowski, F.W. LoGerfo, E.S. Horton, A. Veves, Soluble intercellular adhesion molecule, vascular cell adhesion molecule, and impaired microvascular reactivity are early markers of vasculopathy in type 2 diabetic individuals without microalbuminuria. Diabetes Care 22, 1865–1870 (1999)PubMedCrossRef

41.

C.D. Stehouwer, M.A. Gall, J.W. Twisk, E. Knudsen, J.J. Emeis, H.H. Parving, Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 51, 1157–1165 (2002)PubMedCrossRef

42.

C. Gazzaruso, A. Coppola, C. Falcone, C. Luppi, T. Montalcini, E. Baffero, Transcutaneous oxygen tension as a potential predictor of cardiovascular events in type 2 diabetes. Diabetes Care 36, 1720–1725 (2013)PubMedCrossRef

43.

J. Apelqvist, Diagnostics and treatment of diabetic foot. Endocrine 41, 384–397 (2012)PubMedCrossRef

44.

C. Meisinger, M. Heier, R. Landgraf, M. Happich, H.E. Wichmann, W. Piehlmeier, Albuminuria, cardiovascular risk factors and disease management in subjects with type 2 diabetes: a cross-sectional study. BMC Health Serv. Res. 8, 226 (2008)PubMedCentralPubMedCrossRef

Titel: Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial
verfasst von: Wen-Hao Tang
Fu-Huang Lin
Chien-Hsing Lee
Feng-Chih Kuo
Chang-Hsun Hsieh
Fone-Ching Hsiao
Yi-Jen Hung
Publikationsdatum: 01.03.2014
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 2/2014
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-013-0002-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2014

Effect of combined therapy of human Wharton’s jelly-derived mesenchymal stem cells from umbilical cord with sitagliptin in type 2 diabetic rats

Serum levels of IgG and IgG4 in Hashimoto thyroiditis

How to decide intervention thresholds based on FRAX in central south Chinese postmenopausal women

BRAF V600E assessment by pyrosequencing in fine needle aspirates of thyroid nodules with concurrent Hashimoto’s thyroiditis is a reliable assay

Association between CTLA-4 genetic polymorphisms and susceptibility to osteosarcoma in Chinese Han population